-
Sector Analysis
Polycystic Ovarian Syndrome (PCOS) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Polycystic Ovarian Syndrome (PCOS) Marketed and Pipeline Drugs Report Overview Polycystic Ovarian Syndrome (PCOS) is a complex condition characterized by elevated androgen levels, menstrual irregularities, and/or small cysts on one or both ovaries. It stands as the most prevalent hormonal disorder affecting females of reproductive age. Genetic and environmental factors are responsible for the etiology of this condition. Unhealthy lifestyle choices, dietary habits, or exposure to infectious agents tend to increase the risk of developing PCOS. Key Mechanisms of Action...
-
Sector Analysis
Female Sexual Dysfunction (FSD) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Female Sexual Dysfunction (FSD) Marketed and Pipeline Drugs Report Overview Female sexual dysfunction (FSD) is an umbrella term that encompasses disorders of sexual desire, orgasm, arousal, and sexual pain that result in significant personal distress. FSD is a multifactorial, progressive problem that can occur at any stage of life. It is a complex neurovascular phenomenon that is under the control of psychological, neurovascular, and hormonal factors. Key Mechanisms of Action (Marketed) ·       Receptor Agonist ·       Enzyme Inhibitor ·       Receptor Antagonist...
-
Sector Analysis
Cell and Gene Therapies in CNS Disorders – Disease Overview, Treatment Options and Future Market Assessment
Reasons to buy the ‘Cell and Gene Therapies in CNS Disorders’ report: The report covers the global scope of drug development focusing mainly on the 8MM including the US, 5EU, Japan, and South Korea. The report focuses on the marketed CGT assets addressing CNS disorders as well as the top five CNS disorders with the most CGT pipeline assets. The report throws light on the competitive landscape of leading CGT agents in CNS Disorders including launch date projections, analyst consensus...
-
Sector Analysis
Premature Labor (PL) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Premature Labor (PL) Marketed and Pipeline Drugs Report Overview Premature/preterm labor (PL) is labor occurring after 20 and before 37 weeks gestation. Premature deliveries cause more than half of long-term morbidity and 75% of perinatal mortality. Premature labor is diagnosed primarily by history and symptoms. Symptoms of preterm labor include regular contractions before term gestational age associated with cervical change, pelvic pressure, menstrual-like cramps, watery vaginal discharge, and lower back pain. Although lower back pain is present in normal pregnancy as well,...
-
Sector Analysis
Ovarian Cancer Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2032
Ovarian Cancer Market Report Overview The ovarian cancer market across the 7MM was valued at $3.3 billion in 2022. The market will grow at a CAGR of more than 1% from 2022 to 2032. The 7MM includes the US, France, Germany, Italy, Spain, the UK, and Japan. Ovarian cancer is one of the most lethal gynecological cancers worldwide. Approximately 90% of ovarian cancer cases are epithelial, with distinct sites of origin arising from the ovarian surface epithelium or distal fallopian...
-
Sector Analysis
Acute Ischemic Stroke (AIS) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Acute Ischemic Stroke Competitive Analysis Report Overview AIS is a medical emergency caused by decreased blood flow to the brain, which results in damage to brain cells. It occurs when a blood vessel in the brain is blocked by a clot or mass, impeding blood flow to brain cells. The primary cause of ischemic stroke is atherosclerosis, the accumulation of fatty deposits (plaque) on vessel walls. These deposits can cause two types of obstruction, including cerebral thrombosis and cerebral embolism. Key Mechanisms...
-
Sector Analysis
Gout Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2032
Gout Market Report Overview The Gout market across the 7MM (7MM: the US, France, Germany, Italy, Spain, the UK, and Japan) was valued at $4.63 billion in 2022. Significant growth is expected at a CAGR of more than 8% from 2022 to 2032 as the gout population steadily increases and novel therapies enter the market. The US had the highest number of diagnosed prevalent cases of gout in 2022, followed by France and the UK. Gout is a form of...
-
Sector Analysis
Insomnia Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2032
Insomnia Market Report Overview The Insomnia market across the 7MM (7MM: the US, France, Germany, Italy, Spain, the UK, and Japan) was valued at $3.2 billion in 2022. Steady growth is anticipated at a CAGR of more than 2% from 2022 to 2032, due to the launch of four novel pipeline agents - Hetlioz, SM-1, vornorexant, and sunobinop. The insomnia market research report offers an overview of insomnia, including its epidemiology, symptoms, diagnosis, and disease management. The report offers key...